Literature DB >> 15708228

Paraneoplastic limbic encephalitis.

M E Farrugia1, R Conway, D J Simpson, K M Kurian.   

Abstract

Paraneoplastic limbic encephalitis (PLE) is a rare neurological consequence of a variety of cancers, most commonly originating from lung, breast and testis. The aetiology is believed to be immune-mediated, caused by tumour-induced autoimmunity launching an attack against one's own central nervous system. The patient may present with amnesia, depression, anxiety, seizures and/or personality changes. The onset of these symptoms may precede the diagnosis of malignancy by a period of up to 2 years. The malignancy may be occult and unless the syndrome is recognised, it may fail to be detected. The diagnosis of PLE is suggested by the clinical picture, MRI evidence of mesial temporal lobe abnormality and CSF abnormalities such as the presence of oligoclonal bands. It may be further supported by the presence of paraneoplastic antibodies in the serum. Immunosuppression has been tried in some cases but memory impairment is often irreversible. There are several case reports in the literature of paraneoplastic limbic encephalitis but few emphasise the resulting impact that this may have on the patient's quality of life and their carers. The accompanying amnesia is often far more distressing to the carers, who are aware of the limitations of treatment of the underlying malignancy. Hospices offer the appropriate palliative environment for such patients as well as physical and psychological respite to the carers.

Entities:  

Mesh:

Year:  2005        PMID: 15708228     DOI: 10.1016/j.clineuro.2004.02.029

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  2 in total

1.  A patient with an acute confusional state.

Authors:  Graham Baker; Maurice Jackson; Sanjay Vydianath; Hani Benamer
Journal:  BMJ Case Rep       Date:  2010-12-09

2.  Autoimmune Voltage-Gated Potassium Channel Limbic Encephalitis With Auditory and Visual Hallucinations.

Authors:  Bahadar S Srichawla
Journal:  Cureus       Date:  2022-05-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.